Zürcher Nachrichten - 'Beginning of the end': patients hail new treatment for drug-resistant TB

EUR -
AED 3.823067
AFN 73.044829
ALL 98.563502
AMD 415.895201
ANG 1.874037
AOA 949.259048
ARS 1069.202212
AUD 1.668302
AWG 1.873537
AZN 1.83917
BAM 1.956465
BBD 2.099514
BDT 124.262238
BGN 1.957858
BHD 0.392333
BIF 3074.106551
BMD 1.040854
BND 1.412641
BOB 7.185442
BRL 6.470832
BSD 1.039853
BTN 88.54585
BWP 14.441909
BYN 3.402957
BYR 20400.734368
BZD 2.092411
CAD 1.495342
CDF 2987.249882
CHF 0.936979
CLF 0.037325
CLP 1029.904142
CNY 7.596984
CNH 7.604702
COP 4552.600819
CRC 527.979464
CUC 1.040854
CUP 27.582626
CVE 110.340139
CZK 25.098056
DJF 185.172942
DKK 7.463549
DOP 63.34153
DZD 140.647807
EGP 52.918567
ERN 15.612807
ETB 132.398003
FJD 2.413375
FKP 0.824337
GBP 0.82992
GEL 2.92495
GGP 0.824337
GHS 15.291
GIP 0.824337
GMD 74.941528
GNF 8987.05477
GTQ 8.012687
GYD 217.553948
HKD 8.085035
HNL 26.41998
HRK 7.465946
HTG 135.933555
HUF 411.693074
IDR 16875.362566
ILS 3.799361
IMP 0.824337
INR 88.873562
IQD 1362.16301
IRR 43806.933362
ISK 145.251299
JEP 0.824337
JMD 162.01507
JOD 0.738279
JPY 163.753429
KES 134.394981
KGS 90.554007
KHR 4178.416673
KMF 485.167994
KPW 936.767833
KRW 1517.023168
KWD 0.32077
KYD 0.866595
KZT 538.693106
LAK 22740.72975
LBP 93117.751445
LKR 306.46417
LRD 189.324382
LSL 19.335172
LTL 3.073371
LVL 0.629602
LYD 5.104735
MAD 10.486264
MDL 19.185521
MGA 4904.667134
MKD 61.550922
MMK 3380.652522
MNT 3536.821057
MOP 8.318628
MRU 41.51011
MUR 48.993139
MVR 16.03087
MWK 1803.112892
MXN 21.011455
MYR 4.670284
MZN 66.514439
NAD 19.335172
NGN 1604.621988
NIO 38.263006
NOK 11.81876
NPR 141.621138
NZD 1.843802
OMR 0.400466
PAB 1.039853
PEN 3.872116
PGK 4.220435
PHP 60.985684
PKR 289.4917
PLN 4.261854
PYG 8109.756569
QAR 3.783322
RON 4.979757
RSD 117.008668
RUB 103.961897
RWF 1450.593068
SAR 3.908552
SBD 8.726055
SCR 14.848747
SDG 626.073723
SEK 11.533055
SGD 1.414106
SHP 0.824337
SLE 23.734717
SLL 21826.186791
SOS 594.302008
SRD 36.490207
STD 21543.572066
SVC 9.099093
SYP 2615.176637
SZL 19.343575
THB 35.545453
TJS 11.380187
TMT 3.653397
TND 3.316886
TOP 2.437785
TRY 36.62674
TTD 7.066402
TWD 34.035403
TZS 2518.866428
UAH 43.60062
UGX 3806.293789
USD 1.040854
UYU 46.30153
UZS 13424.563113
VES 53.68216
VND 26463.707719
VUV 123.572247
WST 2.875658
XAF 656.180041
XAG 0.035175
XAU 0.000398
XCD 2.81296
XDR 0.797271
XOF 656.180041
XPF 119.331742
YER 260.603777
ZAR 19.420698
ZMK 9368.931624
ZMW 28.777782
ZWL 335.154497
  • SCS

    0.0800

    11.73

    +0.68%

  • BCE

    0.0600

    22.9

    +0.26%

  • BCC

    0.9500

    123.19

    +0.77%

  • BTI

    0.0400

    36.26

    +0.11%

  • RIO

    -0.0300

    59.2

    -0.05%

  • NGG

    -0.1600

    58.86

    -0.27%

  • GSK

    -0.0300

    34.03

    -0.09%

  • RBGPF

    59.8000

    59.8

    +100%

  • CMSC

    -0.1321

    23.77

    -0.56%

  • JRI

    0.0500

    12.15

    +0.41%

  • CMSD

    0.1000

    23.65

    +0.42%

  • AZN

    -0.3300

    66.3

    -0.5%

  • RELX

    0.3000

    45.89

    +0.65%

  • RYCEF

    -0.0100

    7.24

    -0.14%

  • VOD

    0.0600

    8.43

    +0.71%

  • BP

    0.0400

    28.79

    +0.14%

'Beginning of the end': patients hail new treatment for drug-resistant TB
'Beginning of the end': patients hail new treatment for drug-resistant TB / Photo: Michele Spatari - AFP/File

'Beginning of the end': patients hail new treatment for drug-resistant TB

Volodymyr is celebrating a major milestone on Wednesday -- it's his final day of taking a new treatment hailed as a turning point in the fight against drug-resistant tuberculosis.

Text size:

The 25-year-old doctor in Ukraine's capital Kyiv said he had nasty neurological side effects when he was on a previous drug regimen, which takes up to two years, involves a huge number of pills and is less than 60-percent effective.

But the new treatment course took just six months, and gave him very few side effects. "It was very easy," he told AFP.

A scan on Wednesday showed he was clear of tuberculosis, and he plans to start work next week after eight months off sick.

"Now I can start life again," said Volodymyr, who did not give his last name.

Tuberculosis, once called consumption, was the world's biggest infectious killer before the arrival of Covid-19, with 1.5 million people dying from the disease each year.

Around five percent of new cases are resistant to commonly prescribed antibiotics, making them difficult to treat.

However a new drug regimen, called BPaL because it combines the antibiotics bedaquiline, pretomanid and linezolid, has been seen as a breakthrough since it was first approved by the US Food and Drug Administration in 2019.

- From 23 to five pills a day -

Research in 2020 showed that the BPaL regimen cured more than 90 percent of drug-resistant patients, however there was a high rate of side effects linked to linezolid, including nerve pain and bone marrow suppression.

But a study published in the New England Journal of Medicine on Wednesday indicated that the dosage of linezolid can be halved.

A trial involving 181 participants with drug-resistant tuberculosis was carried out in Russia, South Africa, Georgia and Moldova -- all countries with high TB rates.

It found that while 1,200 milligrams of linezolid over six months had a cure rate of 93 percent, that number only dropped to 91 percent if the dosage was halved to 600 milligrams.

The number of participants with the side of peripheral neuropathy -- which causes nerve pain -- fell from 38 to 24 percent at the lower dosage, while the rate of bone marrow suppression dropped from 22 to two percent.

The study's lead author, Francesca Conradie of South Africa's University of the Witwatersrand, said she was "overwhelmed with how successful this regimen was".

"This is the beginning of the end of drug-resistant TB," she told AFP.

"The quicker you treat someone's TB, the less infectious they are -- it's like Covid in many ways."

It is also far easier for patients to take BPaL, she added, saying previous courses could involve 23 pills a day -- and up to 14,000 total pills over the maximum two-year course.

BPaL involves five pills a day -- and fewer than 750 over six months.

- Could TB surpass Covid? -

Nataliia Lytvynenko, who has overseen BPaL treatments in Ukraine, said the more manageable amount of pills meant it was easier for patients to continue treatment after being displaced by the war in her country.

The World Health Organization indicated earlier this year that it would soon update its guidelines to recommend most patients with drug-resistant TB use BPaL with 600 milligrams of linezolid.

Two experts not involved in Wednesday's study said the research and the WHO guidance were "major advances".

The BPaL treatment "is one of the defining achievements of the tuberculosis research community in this century," Guy Thwaites of Britain's Oxford University and Nguyen Viet Nhung of Vietnam's National Tuberculosis Control Programme wrote in an editorial in the New England Journal of Medicine.

The advances come amid warnings that the pandemic has stalled progress against tuberculosis.

"I very much worry that TB will -- whether it's this year or next -- again become the largest single killer of any infectious disease in the world," said Mel Spigelman, the president of the non-profit TB Alliance which funded the research.

Volodymyr meanwhile said he hoped that progress would continue so the treatment timeline gets even shorter.

"Maybe it will be two months -- or even one," he said with a smile.

F.Carpenteri--NZN